Literature DB >> 7127264

Colon transposition in the management of upper gastrointestinal cancer.

M P Osborne, J D Griffiths, H J Shaw.   

Abstract

Restoration of swallowing after the resection of malignant disease in the upper gastrointestinal tract, including the pharynx, remains a surgical challenge. Recontructive techniques using a viscus are reviewed and 40 consecutive cases treated at the Royal Marsden Hospital (1965-1980) by colon transposition are reported. The major indication for this procedure was postradiation relapse of pharyngolaryngeal cancer requiring pharyngolaryngectomy. In 60% of the cases, a long-segment colon transposition was carried out through a retrosternal tunnel. The presternal subcutaneous route was used in one third of the cases and the posterior mediastinum in 7%. The 30-day operative mortality was 20% overall, but in recent years it was lowered to 7%. The major complications were cervical fistula (25%) and bronchopneumonia (20%), which frequently occurred together in patients who had undergone prior radiation therapy. Colon necrosis occurred in two cases. The functional outcome was satisfactory, with good results in 78%. Late structures due to marginal arteritis were observed if further radiation therapy was used in the cervical region. Where follow-up data was available, the mean survival was 36 months (range, 2-180; median 18 months) and the three-year survival rate was 32%. Colon transposition must remain an alternative to gastric transposition and is a durable esophageal substitute for long-term palliation.

Entities:  

Mesh:

Year:  1982        PMID: 7127264     DOI: 10.1002/1097-0142(19821115)50:10<2235::aid-cncr2820501044>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  1 in total

1.  Colon interposition for esophageal replacement: an alternative technique based on the use of the right colon.

Authors:  H Fürst; W H Hartl; F Löhe; F W Schildberg
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.